The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback